Intellia Therapeutics stock falls following strategic reorganization By Investing.com
Investing.com — Shares of Intellia Therapeutics, Inc. (NASDAQ:) fell 2.4% in pre-open trading Friday as the company announced a strategic reorganization focusing on key value drivers and an anticipated workforce reduction. The Cambridge-based clinical-stage gene editing company unveiled its strategic priorities and key anticipated milestones for 2025, which include focusing resources on high-value programs such as NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis.
The company plans to complete enrollment for the Phase 3 HAELO study of NTLA-2002 in the second half of 2025 and expects to submit a Biologics License Application in the second half of 2026. Intellia also reported…
